AI-driven pipeline iBio is an AI-driven biotechnology company focusing on cardiometabolic and cardiopulmonary diseases, obesity, cancer and other hard-to-treat conditions, presenting multiple collaboration opportunities in AI-enabled drug discovery and computational biology services.

Clinical-stage potential With first-in-human IBIO-600 trials launched in 2026 and a strategy toward clinical-staged development, there are opportunities to engage for translational research, CRO partnerships, and regulatory consulting as iBio advances its candidates.

Strategic partnerships Recent collaborations include a COVID-19 therapeutic program with Planet Biotechnology and ongoing antibody engineering efforts; potential for co-development, licensing, or supply partnerships in biologics and specialized antibodies.

Board and leadership shifts Executive and board changes, including the appointment of Liz as CEO/CSO and new board member Elizabeth Stoner, signal a strategic inflection point that may open doors for advisory services, investor relations collaborations, and strategic partnerships.

Funding and revenue signals Reported revenue in the tens of millions range and active fundraising/visibility with investors indicate an opportunity to offer strategic fundraising advisory, financial analytics, and non-dilutive funding support services to accelerate late-stage development.